A 16-Week, Multicenter, Randomized, Open-Label Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome.

Trial Profile

A 16-Week, Multicenter, Randomized, Open-Label Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2015

At a glance

  • Drugs Aripiprazole (Primary) ; Olanzapine; Quetiapine; Risperidone
  • Indications Metabolic syndrome; Schizophrenia
  • Focus Pharmacodynamics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 28 Apr 2012 Planned number of patients changed from 258 to 860 as reported by European Clinical Trials Database record.
    • 21 Oct 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 21 Aug 2009 Actual patient number changed from 25 to 52 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top